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yn its 16th year, the Transcatheter Cardiovascular Thera-
eutics (TCT) annual meeting remains one of the largest
eetings in interventional cardiology. Live case demonstra-
ions of interventional procedures remain a hallmark of this
eeting, where results of several clinical studies and reviews
f topics of interest for practicing interventional cardiolo-
ists were also presented. This meeting continues to provide
venue for extensive industry exhibits, and the role of
evices used in interventions was prominent. We present
he results of key studies presented at this year’s meeting and
iscuss their clinical implications in addition to summariz-
ng the new techniques and topics presented.
RUG-ELUTING STENTS
ecause of their superiority in reducing restenosis, drug-
luting stents (DES) have replaced the use of bare-metal
tents (BMS). Multiple studies involving DES including
onger-term follow-ups of previously reported trials and
esults of DES use for higher-risk lesion and patient subsets
ere presented at this meeting.
AXUS-IV (two-year results): The Pivitol, Prospective,
andomized Trial of the Slow-rate Release Polymer-
ased Paclitaxel-eluting TAXUS Stent—Greg Stone,
D. This study evaluated the efficacy of a paclitaxel-
luting stent (PES) in reducing restenosis versus a BMS (1).
he investigators randomized 1,314 patients undergoing
lective stenting, with single de novo lesions 10 to 28 mm in
ength, treatable with one stent in vessels 2.5 to 3.75 mm in
iameter. Patients were randomized to a 1-mg/mm2 slow-
elease paclitaxel-eluting Taxus stent (Boston Scientific,
atick, Massachusetts) or a BMS and received clopidogrel
or six months. The primary end point was the nine-month
ate of ischemia-driven target vessel revascularization
TVR). The two groups were matched, and nine-month
VR and target lesion revascularization (TLR) rates were
2.0% and 11.3% with the BMS and 4.7% and 3.0% with
he Taxus stent (risk ratio [RR]  0.39 and RR  0.27,
oth p  0.0001), respectively. There was no difference
etween the two groups in cardiac death, myocardial infarc-
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Manuscript received December 14, 2004, accepted January 5, 2005.ion (MI), or stent thrombosis at nine months. Significant
elative risk reductions of 70% to 80% in TLR were seen in
ost patient and lesion subgroups, including patients with
iabetes, smaller vessels, and longer lesions.
Two-year follow-up data were available for 94% of the
tudy cohort and revealed TVR and TLR rates of 21.1% and
7.4% with the BMS and 10.6% and 5.6% with the Taxus
tent (RR  0.50 and RR  0.32, both p  0.0001),
espectively. There was no difference between the two
roups in cardiac death, MI, or stent thrombosis at two
ears, whereas relative risk reductions of 60% to 70% in
LR were seen with the Taxus stent in most patient and
esion subgroups, except insulin-requiring diabetics, in
hom the difference did not reach statistical significance. Of
mportance, although stent thrombosis rates were low in both
roups (1.1% Taxus stent and 0.8% BMS, p  0.77), three
atients in the Taxus stent group (none in BMS group) had
tent thrombosis between one and two years after Taxus stent
mplantation.
AXUS-II (two-year results): Follow-up Angiography
nd Intravascular Ultrasound (IVUS) Results of the
low-release and Moderate-release Polymer-based
aclitaxel-eluting Stent with a Bare Metal Stent—
ntonio Colombo, MD. The Taxus-II trial was among a
eries of preliminary clinical trials investigating the utility of
ES in reducing restenosis. In this trial, the investigators
andomized 536 patients with single de novo lesions of 10.5
m length in a reference vessel of 2.75 mm diameter to a
low-release (n  131) or moderate-release (n  135)
olymer-based PES and its bare-metal counterpart (n 
70). Six-month results have been presented previously and
evealed TLR reduction of 76% in both the currently
pproved slow-release and non-commercially available
oderate-release PES formulations versus their respective
ontrols.
To demonstrate long-term safety and efficacy, two-year
linical, angiographic, and IVUS results of this study were
resented at this meeting. Target lesion revascularization
as reduced from 15.5% (BMS) to 5.5% (slow-release PES,
 0.0047) and 3.9% (moderate-release PES, p  0.0006)
t two years. The TLR rates between six months and two
ears in all three groups remained unchanged (13.3% vs.
5.5% BMS, 4.6% vs. 5.5% slow-release PES, 3.1% vs. 3.9%
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March 1, 2005:796–801 Highlights of the 2004 TCT Meetingoderate-release PES, respectively, p  NS for all). There
as no difference in the three groups with respect to cardiac
eath, MI, or stent thrombosis at two years. However, five
atients were felt to have late stent thrombosis between six
onths and two years, of whom two patients were in the
low-release and three patients in the moderate-release PES
ormulation. Angiographic substudy results revealed that
inimum luminal diameter between six months and two
ears in the BMS group increased from 1.96  0.47 mm to
.12  0.44 mm (p  0.0001), whereas it remained
nchanged in the slow-release (2.32  0.39 mm vs. 2.32 
.45 mm, p  NS) and moderate-release (2.34  0.38 mm
s. 2.35  0.37 mm, p  NS) PES formulations. No
oronary artery aneurysm formation was noted at two years
ith either of the paclitaxel formulation-treated patients.
he IVUS evaluation at two years revealed in-stent volume
bstruction of 17.07  12.21% in the BMS group, 10.59 
.43% in the slow-release (p  0.0018 vs. BMS), and 11.93
9.67% in the moderate-release (p  0.0139 vs. BMS)
ES groups. By IVUS evaluation, incomplete stent appo-
ition at two years was reported in 9.0% of BMS, 8.7% of
low-release (p  NS vs. BMS), and 6.5% of moderate-
elease (p  NS vs. BMS) PES groups, respectively.
IABETES: A Prospective Randomized Controlled Trial
f the Polymer-based Sirolimus-eluting Stent Versus a Bare
etal Stent in Patients with Diabetes Mellitus—Manel
abate, MD. Diabetic patients have higher restenosis rates
fter coronary stenting. In this multicenter trial, the investiga-
ors randomized 160 patients (221 lesions) with diabetes
ellitus (oral hypoglycemic or insulin-treated) and de novo
ative coronary artery lesions to the sirolimus-eluting Cypher
tent (Cordis, Miami, Florida) versus its BMS counterpart.
he two groups were matched for baseline clinical and angio-
raphic characteristics, and one-third of the patients were
nsulin-treated in both groups. The primary end point of
n-stent and in-segment (5 mm proximal and distal to stent
dge) late loss in minimum luminal diameter at nine months
y quantitative coronary angiography was reduced by 82%
0.44 mm BMS vs. 0.08 mm Cypher stent, p  0.0001), and
he secondary end point of in-segment restenosis was reduced
y 76% (33% BMS vs. 7.7% Cypher stent, p  0.0001) with
he Cypher stent. These angiographic findings correlated with
omparative reductions in TLR and major adverse cardiac
vent (MACE) (cardiac death, MI, and TLR) rates at nine
onths (BMS: TLR 31.3%, MACE 36.3%; Cypher stent:
LR 7.5%, MACE 11.3%, p  0.0001 for both). Compara-
ive relative risk reductions were noted in both insulin-
equiring and oral hypoglycemic-treated diabetics.
rterial Revascularization Therapies Study (ARTS) II—
atrick Serruys, MD. ARTS I was a large, randomized,
ulticenter trial, which evaluated complete arterial revascu-
arization with coronary artery bypass graft surgery (CABG)
ersus multivessel stenting (with BMS) in 1,205 patients
ith multivessel coronary artery disease (CAD). No signif-
cant difference in death, stroke, or MI between the two
roups was noted, although there was a 17% reduction in w2-month repeat revascularization with CABG but at a
igher cost than multivessel PCI (2). In ARTS II, 607
atients with multivessel CAD were enrolled in a registry
nd treated with the sirolimus-eluting Cypher stent. This
tudy was designed to compare one-year major adverse
ardiac and cerebrovascular event rates between Cypher
tent treated patients against the historical control CABG
roup (n  600) from ARTS I.
The patients enrolled in ARTS II had a higher prevalence
f diabetes, hypertension, and hypercholesterolemia than
atients in ARTS I. Periprocedural use of glycoprotein
GP) IIb/IIIa inhibitors, lesion complexity, and frequency
f three-vessel stenting, the number of lesions treated/
atient (ARTS II: 3.2, ARTS I-CABG: 2.6, ARTS
-percutaneous coronary intervention [PCI]: 2.5) and stent
ength (ARTS II: 73 mm; ARTS I-PCI: 48 mm) were all
reater in ARTS II. Despite the greater risk and complexity
nherent in this ARTS II cohort, 30-day MACE rate was
.8% compared with 5.3% for the ARTS I-CABG and
.2% for the ARTS I-PCI groups. Six-month MACE rates
ere 6.4%, 9.0%, and 20.0%, in the three groups, respec-
ively (p  NS for all comparisons).
MPLICATIONS. One year ago the results of the Taxus-IV
rial were reported and the benefit of PES in all lesion
ubtypes and patient populations, including diabetics, was
ound to be clinically significant and consistent. However,
onger-term safety and efficacy data were lacking. Two-year
esults of both the Taxus-II and -IV trials are reassuring in
hat no late restenosis catch-up or late coronary artery
neurysm formation has been noted with PES. The initial
enefit in lower TLR rates remains at two years after the
ndex procedure, resulting in lower MACE rates at two
ears and confirming the efficacy of PCI with PES as a
ong-term revascularization strategy. On a cautionary note,
mong the PES-treated patients in both trials, eight patients
0.9%) were felt to have late stent thrombosis between six
onths and two years, whereas no BMS-treated patients had
ate-stent thrombosis in either trial. Although this rate of
ate-stent thrombosis is low and deemed to be not statisti-
ally significant by the investigators, it is extremely concern-
ng, as this is an underappreciated phenomenon. A recent
eport by McFadden et al. (3) describes late-stent throm-
osis in patients treated with both Taxus and Cypher stents
nd further raises questions regarding long-term safety of
oth of these DES especially with discontinuation of
ntiplatelet therapy. These data suggest that longer-term
ual antiplatelet therapy with aspirin and clopidogrel than
he currently recommended three to six months after DES
mplantation may be required. The reasons behind late-
tent thrombosis with DES remain unclear and need further
nvestigation. As the phenomenon has been reported with
oth of the currently available DES, and the duration of
rug elution is significantly different between the two stents,
t is unlikely that the duration of drug elution is associated
ith late-stent thrombosis. The IVUS data would suggest
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Highlights of the 2004 TCT Meeting March 1, 2005:796–801hat poor stent strut apposition with DES is also not
esponsible for this problem, so an inflammatory response to
he underlying polymer (4) or withdrawal of antiplatelet
herapy may be the underlying mechanism. Regardless, an
ntensive after-marketing surveillance of DES should be
erformed by clinicians, industry, and regulatory bodies to
nsure that the restenosis benefit is not counteracted by
ife-threatening late-stent thrombosis.
Both the sirolimus-eluting Cypher and paclitaxel-eluting
axus stents are superior to BMS in reducing restenosis and
LR (1,5). The Diabetes trial presented at this meeting
emonstrates that Cypher stents are clearly beneficial in
educing neointimal proliferation in diabetics, and data
rom the Taxus-IV trial (1) support that the same holds true
or Taxus stents. Although these are not comparative data
etween these two stents, it is reassuring that in a subset of
atients with the highest restenosis rate (diabetics), both
ommercially available DES offer low restenosis rates. Ab-
tracts presented at this and other recent meetings confirm
ow restenosis rates with Cypher and Taxus stents in
atients with long lesions, calcified lesions, chronic total
cclusions, bifurcation lesions, and in-stent restenotic le-
ions. Data from ARTS II demonstrate that in the contem-
orary treatment of patients with multivessel CAD, stenting
ith Cypher stents offers six-month clinical outcomes
omparable to CABG. Data with DES are accumulating in
igh-risk restenosis lesions, but as comparative data be-
ween various DES are limited, it appears that stent choice
ontinues to be based on cost and stent deliverability.
tudies utilizing ABT-578 and everolimus-eluting stents
ontinue to appear promising, demonstrating low late-loss
ndices and restenosis rates.
CUTE MYOCARDIAL INFARCTION
rimary PCI is the preferred revascularization modality for
atients suffering an acute ST-segment elevation MI
STEMI) and this has resulted in lower mortality rates and
nfarct sizes for these patients (6). Recently multiple studies
ave been designed and completed to evaluate various
echniques for myocardial preservation during PCI for
TEMI patients. Systemic hypothermia, intracoronary hy-
eraqueous oxygen, mechanical thrombectomy with the
-sizer catheter (ev3, Plymouth, Minnesota), and distal
icrovascular protection with the GuardWire (Medtronic,
inneapolis, Minnesota) all proved to be futile in the
reatment of patients with STEMI when tested in a
andomized clinical trial (7,8). Studies presented at this
ear’s TCT meeting addressed an additional adjunctive
herapy for treating STEMI patients.
IMI: Angiojet Rheolytic Thrombectomy in Patients Un-
ergoing Primary Angioplasty for Acute Myocardial Infarc-
ion—Arshad Ali, MD. This trial used Angiojet Rheolytic
hrombectomy (Possis, Minneapolis, Minnesota) prior to
CI for patients suffering from large STEMIs to test whetherhrombus extraction prior to PCI leads to reduction in final tnfarct size. The investigators randomized 480 STEMI pa-
ients with anterior or large inferior myocardial infarcts of12
duration to primary PCI or Angiojet Thrombectomy fol-
owed by PCI. Patients with left ventricular dysfunction
ejection fraction35%), cardiogenic shock, previous CABG,
ncontrolled hypertension, major surgery within 6 weeks,
troke within 30 days or GP IIb/IIIa inhibitor contraindication
ere excluded from the trial. The two groups were matched in
aseline clinical characteristics, target vessel revascularized,
ime to PCI, use of stents and GP IIb/IIIa inhibitors, baseline
hrombus burden, and Thrombolysis In Myocardial Infarction
TIMI) flow grade in culprit vessel. However, in the throm-
ectomy group, total procedural time was prolonged (76 vs.
0 min, p  0.0001) and temporary transvenous pacemaker
se was greater (58% vs. 16%, p  0.0001). Analysis revealed
hat final TIMI flow grade 3 was achieved in only 92% of
atients in the thrombectomy group and in 97% of patients in
he standard PCI group (p  0.02), with no difference in
yocardial blush score, corrected TIMI frame counts, or
T-segment resolution with either strategy. Periprocedural
linical and angiographic complications were comparable in
oth groups. The primary end point of final infarct size at 14
o 28 days after MI by Tc-99m sestamibi SPECT imaging was
igher in the thrombectomy group (12.5  12.1% thrombec-
omy vs. 9.8  10.9% control, p  0.02), and this difference
as most pronounced in inferior infarcts (10.2  11.1%
hrombectomy vs. 6.5  8.9% control, p  0.005), whereas it
as not different in anterior infarcts (16.5 13.1% thrombec-
omy vs. 15.3  12.0% control, p  0.58). Secondary end
oint of 30-day MACE (death, Q-wave MI, stroke, urgent
ABG, and TLR) was 6.7% in the thrombectomy group and
.7% in the control group (p  0.01), whereas the secondary
nd point of ejection fraction at 14 to 28 days was the same in
oth groups (51  12% thrombectomy vs. 52  11% control,
 0.38). Most importantly, the thrombectomy group had higher
0-day mortality (4.6% thrombectomy vs. 0.8% control, p 
.02).
MPLICATIONS. Recent trials addressing the treatment of
atients with STEMI should serve as reminders of the
ritical need for randomized clinical trials when new devices
r therapies are introduced for clinical use. Although
ntuitively thrombus extraction before PCI in STEMI
atients should be effective, the results of the currently
eported AIMI trial not only question the routine use of the
ngiojet Thrombectomy device for these patients, but
uestion its safety. The increased time to treatment, re-
uirement of adjunctive temporary pacemaker, higher mor-
ality, and larger infarct size in patients treated with this
evice should lead to the avoidance of this device. With
hese data in hand, even in the presence of large intracoro-
ary thrombus burden, the X-sizer thrombectomy device or
ronto extraction catheter (Vascular Solutions, Minneapolis,
innesota) are safer devices to use. In fact, preliminary data
rom a randomized clinical trial utilizing the Pronto extrac-
ion catheter in STEMI patients were presented at TCT
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March 1, 2005:796–801 Highlights of the 2004 TCT Meetingnd indicated the efficacy of this device without compro-
ising in patient safety (9). Further analyses from previ-
usly reported trials were also presented, and it appears that
n selected subgroups of patients both hyperaqueous oxygen
nd cooling to a body temperature of 32°F may lead to
nfarct size reduction. This appears promising and requires
urther investigation.
AROTID STENTING
s symptomatic patients with 50% internal carotid artery
tenosis or asymptomatic patients with 80% stenosis have
ower stroke and death rates with carotid endarterectomy
CEA) than medical therapy (10–12), most current studies
esigned to test the safety and efficacy of carotid stenting are
nrolling such patients. On the basis of the results of a
andomized trial (13), carotid stenting has been shown to be
on-inferior to CEA for patients with high-risk surgical
haracteristics for CEA. The results of this and other
tudies have led to the Food and Drug Administration
pproval of carotid stenting for the treatment of obstructive
arotid artery stenosis, and the treatment paradigm is
apidly shifting from CEA to percutaneous stenting. Nu-
erous randomized and registry studies with newer stent
nd distal protection devices for the treatment of carotid
rtery stenosis are ongoing, and the results of two such
tudies were presented at TCT.
ABERNET: Carotid Artery Revascularization Using
he Boston Scientific FilterWire and the EndoTex Nex-
tent—L. Nelson Hopkins, MD. In this multicenter
rospective registry, the investigators enrolled 480 patients
ith carotid artery stenosis who were high-risk surgical
andidates for CEA to carotid stenting with the nitinol
elf-expanding EndoTex NexStent (Boston Scientific) in
onjunction with the FilterWire (Boston Scientific) distal
mbolic protection. Symptomatic patients with an internal
arotid artery stenosis50%, or asymptomatic patients with
80% (ultrasound)/60% (angiography) stenosis and having
t least one high-risk comorbidity for CEA were enrolled.
he study population was elderly with a mean age of 72.5
.6 years, 65.2% men, with 79.8% de novo lesions in a
ajority of asymptomatic patients (75.6%). Procedural suc-
ess with stent and distal embolic protection was achieved in
6.9% of the patients with stenosis reduction from 83.6% to
.5%. The primary end point of 30-day major adverse event
MAE) (death: 0.5%, MI: 0.2%, and any stroke: 3.4%) rate
as reported to be 3.8%. Major stroke rate was 1.4%,
hereas minor stroke rate was 2.0%.
AVERICK II (30-day results): Evaluation of the
edtronic AVE Self-expanding Carotid Stent System in
he Treatment of Carotid Stenosis—Stephen R. Ramee,
D. In this prospective multicenter registry, 399 patients
ith carotid artery stenosis who were at high risk for CEA
ere enrolled. They were treated with a self-expanding stent exponent (Medtronic, Minneapolis, Minnesota) and the
uardWire (Medtronic) distal embolic protection system.
lthough the one-year MAE (death, MI, ipsilateral stroke)
ate is the primary end point and these data are still being
ollected, secondary end points of the study included acute
rocedural success and 30-day MAE rate. Acute procedural
uccess defined as the successful placement of the stent
with distal embolic protection) with a final residual stenosis
f 30% in the absence of in-hospital MAE, was reported
o be 90.1%. Thirty-day MAE rate was 5.3% (death: 1.0%,
I: 2.0%, ipsilateral stroke: 3.3%).
MPLICATIONS. Patients who are deemed to be at high risk
or surgical complications during CEA include elderly
atients (80 years old), patients with significant cardiac or
ulmonary disease, patients with contralateral carotid occlu-
ion or contralateral laryngeal nerve palsy, previous radical
eck surgery or radiation therapy, and restenosis after CEA.
atients with any one of these high-risk characteristics for
EA were enrolled in a randomized clinical trial comparing
EA to carotid stenting, and results of this trial demon-
trate that these patients can be successfully treated with
ercutaneous carotid stenting with results that are not
on-inferior to CEA (13). Data from two different regis-
ries presented at this meeting add to the fund of knowledge
egarding the safety and short-term efficacy of carotid
tenting with newer stents and distal embolic protection
evices for high-risk CEA patients. The Carotid Revascu-
arization Endarterectomy versus Stent Trial (CREST) is a
ational Institutes of Health/National Heart, Lung, and
lood Institute-funded study in which the investigators are
andomizing 2,500 patients at low risk for surgical compli-
ations during CEA to carotid stenting versus CEA to
valuate both strategies for carotid revascularization in
ow-risk patients. As distal embolic protection devices are
urther improved, anticoagulation regimens optimized and
laque characterization improved, further lowering in pro-
edural complication rates and improvement in both short-
erm and long-term outcomes can be expected with carotid
tenting for all patients.
APHENOUS VEIN GRAFT (SVG) INTERVENTIONS
atients with degenerated SVGs who require percutaneous
evascularization are a difficult subset of patients to treat.
his is primarily owing to high restenosis rates in SVG
esions and distal embolization of macro- and micro-
articulate material during interventional treatment of
VGs, resulting in a 30-day MACE (death, MI, emergency
ABG, or TLR) rate of 16.5% without distal embolic
rotection and 9.6% to 11.6% with distal embolic protection
14,15). Studies addressing SVG interventions with newer
istal embolic protection devices and polytetrafluoroethyl-
ne (PTFE)-covered stents were presented at this meeting.
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Highlights of the 2004 TCT Meeting March 1, 2005:796–801RIDE: A Multicenter, Randomized Trial of Protection
uring Saphenous Vein Graft Intervention to Prevent
istal Embolization—Joseph P. Carrozza, Jr.,
D. This study was initiated with the intention to prove
he superiority of the TriActiv (Kensey Nash Corp., Exton,
ennsylvania) distal occlusion and extraction system in
educing MACE over standard SVG intervention without
istal embolic protection. After the initial 62 patients were
andomized in this trial, results of two randomized trials
onfirmed the utility of distal embolic protection during
VG interventions (14,15) resulting in the routine use of
istal embolic protection during SVG interventions. This
esulted in a change in the study design to a non-inferiority
tudy and the control arm became distal embolic protection
ith either the GuardWire (Medtronic) or FilterWire
Boston Scientific). The investigators then randomized 631
atients with lesions of any length in SVGs (3 to 5 mm
iameter) to either the TriActiv system (n  313) or
uardWire (n 236)/Filterwire (n 83) systems. The two
roups were matched with respect to clinical and angio-
raphic characteristics and target vessel revascularized. Pro-
edural success (89.4% TriActiv; 90.5% control, p  0.64)
as comparable between the two groups and the primary
nd point of 30-day MACE (death, MI, emergent CABG,
r TVR) (11.2% TriActiv; 10.1% control,   1.1%,
ne-sided confidence interval on the difference 5.2%) met
he prespecified criteria for non-inferiority. A secondary
fficacy end point of final TIMI flow grade 3 was achieved
n 99.1% of TriActiv patients and 97.8% of the control
roup (p  0.20). Several secondary safety end points of
I, in-hospital MACE, and stroke were reported to be
omparable between the two groups. However, the TriActiv
roup of patients had higher vascular and hemorrhagic
omplications (11.8% vs. 6.6% control, p  0.02), primarily
hen 8-F sheaths were used.
APTIVE: Cardioshield Application Protects During
ransluminal Intervention of Vein Grafts by Reducing
mboli—David R. Holmes, Jr., MD. This was another
rospective, multicenter, randomized trial initially designed
o prove the superiority of the Cardioshield (Abbott Labo-
atories, Abbot Park, Illinois) distal embolic protection filter
n reducing MACE over standard SVG intervention with-
ut distal embolic protection. After 197 patients were
nrolled in this trial, based on the results of the Saphenous
ein graft Angioplasty Free of Emboli Randomized
SAFER) trial (14), distal embolic protection became to be
tilized routinely for SVG interventions. Therefore, this
rial design was modified to a non-inferiority study design of
he Cardioshield versus GuardWire (Medtronic) distal em-
olic protection and another 652 patients were enrolled in
he non-inferiority arm of the trial. Data analysis of the
nitial superiority cohort (n  197 patients) revealed that
he primary end point of 30-day MACE (death, MI, TLR,
nd emergency CABG) rate was the same in both groups
10.4% Cardioshield vs. 11.9% no distal embolic protection,
 0.82). oFor the larger cohort of patients enrolled in the non-
nferiority arm of the trial (n  652), baseline clinical and
ngiographic characteristics and procedural success did not
iffer between the two groups. However, 30-day MACE
ates were higher in the Cardioshield group (11.4% vs. 9.1%
uardWire, p  0.057). This did not meet the predefined
riteria for non-inferiority of the Cardioshield distal em-
olic protection system.
YMBIOT III: A Prospective Randomized Trial of a
TFE Self-expanding Stent Graft During SVG Inter-
ention–Late Results—Maurice Buchbinder, MD. Both
istal embolization during PCI and restenosis after the index
rocedure affect success of SVG interventions. The PTFE-
overed stents have the potential to reduce distal embolization
nd may also serve as a barrier for smooth muscle cell
roliferation. To investigate this hypothesis, the investigators
andomized 400 patients with lesions up to 41 mm in length,
n SVGs of 3.5 to 5.5 mm, to any BMS against a PTFE-
overed nitonol stent (Symbiot, Boston Scientific). The two
roups were matched in baseline clinical and angiographic
haracteristics, and target vessel revascularized but total stent
ength was longer in the Symbiot stent group (32.5 14.9 mm
s. 26.2  13.6 mm, p  0.0001). Eight-month MACE
death, MI, clinically driven TVR, and TLR) rates (26.6%
MS vs. 30.6% Symbiot stent, p 0.43) and stent thrombosis
ates (2.5% BMS vs. 3.5% Symbiot stent, p  0.16) were
omparable between the two groups. The primary end point of
he study, eight-month angiographic stenosis, was higher in
he analysis segment for the Symbiot stent group (40.1 
9.8% Symbiot stent vs. 34.8  26.3% BMS, p  0.12),
hough this did not reach statistical significance. Binary reste-
osis was higher in the Symbiot stent group (34.9% Symbiot
tent vs. 23.3% BMS, p  0.04) and this led to a higher rate
f TLR requiring percutaneous revascularization in the Sym-
iot stent group (17.9% Symbiot stent vs. 10.4% BMS, p 
.04).
MPLICATIONS. Distal embolic protection during SVG in-
erventions is the current standard for successful outcomes
fter percutaneous revascularization for SVG disease. Inter-
stingly, two trials with newer generation devices were
resented at this meeting in which a filter device (Car-
ioshield) did not prove to be non-inferior to the distal
cclusion and aspiration device GuardWire while another
cclusion and extraction system TriActiv proved to be
on-inferior. The fundamental difference in these two
ewer systems is that one completely occludes the culprit
essel (TriActiv), whereas the other allows blood flow but
an capture debris (Cardioshield). Intuitively, the occlusion
nd aspiration systems should prove to be superior but
ractically, a number of patients do not tolerate these
evices. Generally, the filter devices are better tolerated by
atients, as prolonged ischemic time is not associated with
hem. Unfortunately, the Cardioshield device failed the
on-inferiority test against the GuardWire but, as pointed
ut in the presentation, this difference could be accounted
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March 1, 2005:796–801 Highlights of the 2004 TCT Meetingor by a single clinical event. Nevertheless, with the cur-
ently available data it may be hard for this device to be
pproved for routine clinical use. Both the GuardWire and
he FilterWire are commercially available, and the TriActiv
ystem appears to be a reasonable alternative. The results of
he SYMBIOT III trial verify the futility of PTFE-coated
tents for reducing restenosis and distal embolization. In
act, the higher restenosis rate seen with the Symbiot stent
ver a BMS should lead to greater vigilance in detecting
estenosis after PTFE-covered stent placement for coronary
erforations, currently the only accepted indication for the
se of a PTFE-covered stent.
UMMARY
he results of several new studies relevant to interventional
ardiovascular medicine were presented at this meeting. The
eld of interventional cardiology has morphed into that of
nterventional cardiovascular medicine and this was clearly
vident at this year’s TCT meeting. Though live case
emonstrations of routine coronary interventional proce-
ures were becoming redundant at this meeting, demon-
trations of new techniques and concepts for complex
oronary, peripheral vascular, and carotid interventions at
he meeting this year were educational and relevant. Drug-
luting stents, only recently discovered, are now routinely
sed for most coronary interventions. Data presented at this
eeting confirmed the short- and long-term efficacy of
ES for complex lesion and patient subsets. On a surprising
ote, most recent adjunctive therapies for acute MI patients
ave been unsuccessful, and further investigative efforts are
equired in this area to limit myocardial damage during
TEMI and possibly regenerate myocardium.
Many clinical trials are either ongoing or in the late stages of
rganization to better define the indications and therapies for
eripheral vascular interventions. The utility of drug-eluting
tents for peripheral vascular indications will be a major focus
f investigation over the next few years. Furthermore, percu-
aneous treatments for patients with structural heart disease
ncluding patent foramen ovale closure, mitral annuloplasty,
ortic valve replacement, and left atrial obliteration for atrial
brillation are currently in clinical trials.eprint requests and correspondence: Dr. Ehtisham Mahmud,
CSD Medical Center, 200 West Arbor Drive, San Diego,
alifornia 92103-8411. E-mail: emahmud@ucsd.edu.
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